BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2026-07

194 industry Phase 2/3 trial readout(s) and 48 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2026-06 | 2026-08 →

FDA decision events

DateEventStatusCompanyDrugSource
2026-07-01FDA approvalapprovedNOVARTIS NVSKISQALI FEMARA CO-PACKApproved 2026-07-01: KISQALI FEMARA CO-PACK (COPACKAGED) (NDA209935 SUPPL33)
2026-07-01FDA approvalapprovedNOVARTIS NVSKISQALIApproved 2026-07-01: KISQALI (NDA209092 SUPPL27)
2026-07-01 (month)PDUFA date (company-disclosed)date passedImmunome Inc. IMNMvaregacestatPDUFA July 2026 - Immunome Inc. (varegacestat)
2026-07-01 (half)PDUFA date (company-disclosed)date passedUltragenyx Pharmaceutical Inc. RAREPDUFA second half of 2026 - Ultragenyx Pharmaceutical Inc.
2026-07-02Complete response lettercomplete responseAscelia Pharma AB(PN) (manganese chloride tetrahydrate — powder for oral solution)CRL 2026-07-02: Ascelia Pharma AB NDA 220544 ((PN) (manganese chloride tetrahydrate — powder for oral solution))
2026-07-07FDA approvalapprovedGLENMARK SPECLTRYALTRISApproved 2026-07-07: RYALTRIS (NDA211746 SUPPL11)
2026-07-07FDA approvalapprovedVERA THERAPEUTICS INC. VERATRUTAKNAApproved 2026-07-07: TRUTAKNA (BLA761486 ORIG1)
2026-07-09Complete response lettercomplete responseJiangsu Hengrui Pharmaceuticals Co., Ltd. JHPCYSHR- 1210CRL 2026-07-09: Jiangsu Hengrui Pharmaceuticals Co., Ltd. BLA 761308 (SHR- 1210 injection)
2026-07-09Complete response lettercomplete responseElevar Therapeutics Inc.rivoceranibCRL 2026-07-09: Elevar Therapeutics Inc. NDA 216586 (rivoceranib tablet)
2026-07-09FDA approvalapprovedAMNEAL AMRXSODIUM BICARBONATEApproved 2026-07-09: SODIUM BICARBONATE (NDA220790 ORIG1)
2026-07-09FDA approvalapprovedSANOFI-AVENTIS U.S. LLC SNYSARCLISA ESCENAApproved 2026-07-09: SARCLISA ESCENA (BLA761445 ORIG1)
2026-07-10FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2026-07-10: KEYTRUDA (BLA125514 SUPPL194)
2026-07-10FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDA QLEXApproved 2026-07-10: KEYTRUDA QLEX (BLA761467 SUPPL12)
2026-07-10FDA approvalapprovedPROVEPHARM SASZYOGREENApproved 2026-07-10: ZYOGREEN (NDA218579 ORIG1)
2026-07-10FDA approvalapprovedASTELLASPADCEVApproved 2026-07-10: PADCEV (BLA761137 SUPPL37)
2026-07-13FDA approvalapprovedEISAI INCLEQEMBI IQLIKApproved 2026-07-13: LEQEMBI IQLIK (BLA761375 SUPPL1)
2026-07-13FDA approvalapprovedELI LILLY AND CO LLYVERZENIOApproved 2026-07-13: VERZENIO (NDA208716 SUPPL21)
2026-07-14FDA approvalapprovedCELCUITY CELCREVTORPYKApproved 2026-07-14: REVTORPYK (NDA219908 ORIG1)
2026-07-14FDA approvalapprovedELI LILLY AND CO LLYRETEVMOApproved 2026-07-14: RETEVMO (NDA218160 SUPPL7)
2026-07-14FDA approvalapprovedELI LILLY AND CO LLYRETEVMOApproved 2026-07-14: RETEVMO (NDA213246 SUPPL17)
2026-07-15FDA approvalapprovedMSDLIPFENDRAApproved 2026-07-15: LIPFENDRA (NDA220848 ORIG1)
2026-07-16FDA approvalapprovedMUNDIPHARMAREZZAYOApproved 2026-07-16: REZZAYO (NDA217417 SUPPL7)
2026-07-16FDA approvalapprovedNOVARTIS NVSFABHALTAApproved 2026-07-16: FABHALTA (NDA218276 SUPPL7)
2026-07-16FDA approvalapprovedSUN PHARMA GLOBALILUMYAApproved 2026-07-16: ILUMYA (BLA761067 SUPPL27)
2026-07-19FDA approvalapprovedNOBLE GAS SOLUTIONS INC. NEAIRApproved 2026-07-19: AIR (NDA221805 ORIG1)
2026-07-21Complete response lettercomplete responseApiject Systems Corp.glycopyrrolateCRL 2026-07-21: Apiject Systems Corp. NDA 219107 (glycopyrrolate solution)
2026-07-22FDA approvalapprovedNUVALENTJIDEYTROApproved 2026-07-22: JIDEYTRO (NDA220185 ORIG1)
2026-07-23FDA AdComheldAdCom 2026-07-23: Pharmacy Compounding Advisory Committee
2026-07-23FDA approvalapprovedSCPHARMACEUTICALSFUROSCIX FUROSCIX READYFLOWApproved 2026-07-23: FUROSCIX; FUROSCIX READYFLOW (AUTOINJECTOR) (NDA209988 SUPPL7)
2026-07-23FDA approvalapprovedAETERNA ZENTARISMACRILENApproved 2026-07-23: MACRILEN (NDA205598 SUPPL5)
2026-07-24FDA approvalapprovedASTELLASXTANDIApproved 2026-07-24: XTANDI (NDA213674 SUPPL16)
2026-07-24FDA approvalapprovedOUTLOOK THERAPEUTICS, INC. OTLKLYTENAVAApproved 2026-07-24: LYTENAVA (BLA761320 ORIG1)
2026-07-24FDA approvalapprovedKENVUE BRANDSTYLENOL WITH NAPROXENApproved 2026-07-24: TYLENOL WITH NAPROXEN (NDA219962 ORIG1)
2026-07-24FDA approvalapprovedMERIDIAN BIOSCIENCE MRBKIDKIT:HPApproved 2026-07-24: IDKIT:HP (NDA021314 SUPPL14)
2026-07-24FDA approvalapprovedEMERGE BIOSCIENCE PTE. LTD.GARZULYSApproved 2026-07-24: GARZULYS (BLA761497 ORIG1)
2026-07-24FDA approvalapprovedOTSUKASIMTRIYOApproved 2026-07-24: SIMTRIYO (NDA218145 ORIG1)
2026-07-24FDA approvalapprovedASTELLASXTANDIApproved 2026-07-24: XTANDI (NDA203415 SUPPL26)
2026-07-28FDA approvalapprovedVIATRIS SPECIALTY VTRSGWYN LOApproved 2026-07-28: GWYN LO (NDA219990 ORIG1)
2026-07-29FDA AdComheldCapricor, Inc. CAPRAdCom 2026-07-29: Cellular, Tissue, and Gene Therapies Advisory Committee - BLA 125842
2026-07-29FDA AdComheldCapricor, Inc. CAPRAdCom 2026-07-29: Cellular, Tissue, and Gene Therapies Advisory Committee - BLA 125842
2026-07-29Complete response letterapproved sinceFresenius Kabi USA, LLCGlycophosCRL 2026-07-29: Fresenius Kabi USA, LLC NDA 220381/Original 2, NDA 220381 (Glycophos (sodium glycerophosphate injection))
2026-07-29FDA approvalapprovedFRESENIUS KABI USAGLYCOPHOSApproved 2026-07-29: GLYCOPHOS (NDA220381 ORIG1)
2026-07-29FDA approvalapprovedCMP DEV LLCQLONILIKApproved 2026-07-29: QLONILIK (NDA221094 ORIG1)
2026-07-29PDUFA date (company-disclosed)date passedOutlook Therapeutics, Inc. OTLKbevacizumab-vikgPDUFA July 29, 2026 - Outlook Therapeutics, Inc. (bevacizumab-vikg)
2026-07-30FDA AdComheldReplimune, Inc. REPLAdCom 2026-07-30: Cellular, Tissue, and Gene Therapies Advisory Committee - BLA 125827
2026-07-30FDA AdComheldReplimune, Inc. REPLAdCom 2026-07-30: Cellular, Tissue, and Gene Therapies Advisory Committee - BLA 125827
2026-07-31FDA approvalapprovedNOVARTIS NVSPLUVICTOApproved 2026-07-31: PLUVICTO (NDA215833 SUPPL37)
2026-07-31FDA approvalapprovedDR REDDYS LABS SAZIMRIXBYApproved 2026-07-31: ZIMRIXBY (BLA761376 ORIG1)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-07 est.P2AbbVie ABBVNCT03539536 Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerNon-small Cell Lung Canceractive not recruiting270
2026-07 est.P3AMAG Pharmaceuticals, Inc.NCT03893045 A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric SubjectsIron Deficiency Anemiarecruiting75
2026-07 est.P3Infan Industria Quimica Farmaceutica NacionalNCT04069286 EFFICACY OF ORAL AROEIRA (Schinus Terebinthifolia Raddi) COMPARED TO OMEPRAZOLE IN DYSPEPPSIADyspepsianot yet recruiting474
2026-07 est.P1/P2PT. Prodia Stem Cell IndonesiaNCT04314687 Stem Cell and Conditioned Medium for Cerebral PalsyCerebral Palsyactive not recruiting78
2026-07 est.P3EMSNCT04670666 Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes MellitusType 2 Diabetes Mellitusrecruiting270
2026-07 est.P3HUYABIO International, LLC.NCT04674683 Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced MelanomaUnresectable or Metastatic Melanoma; Progressive Brain Metastasisactive not recruiting450
2026-07 est.P2AkesoNCT04736823 A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLCNSCLCactive not recruiting265
2026-07 est.P3EMSNCT05028140 Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes MellitusType II Diabetesrecruiting480
2026-07 est.P3Akebia Therapeutics AKBANCT05082571 Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney DiseaseAnemia of Chronic Kidney Diseasewithdrawn
2026-07 est.P3Akebia Therapeutics AKBANCT05082584 Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-StimulatingAnemia of Chronic Kidney Diseasewithdrawn
2026-07 est.P1/P2Prestige Biopharma Limited PBHNCT05141149 First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic CancerPancreatic Canceractive not recruiting80
2026-07 est.P2Woolsey PharmaceuticalsNCT05218668 Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)Amyotrophic Lateral Sclerosisactive not recruiting40
2026-07 est.P3ZZ Biotech, LLCNCT05484154 Efficacy and Safety Evaluation of 3K3A-APC in Ischemic StrokeIschemic Strokewithdrawn
2026-07 est.P1/P2CJ Bioscience, Inc.NCT05877430 Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic CancerNSCLC; HNSCC; Melanoma; Metastatic Cancer; Advanced Solid Tumor; Advanced Cancerrecruiting160
2026-07 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT05943795 A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell CarcinomaNon-small Cell Lung Adenocarcinoma; Squamous Cell Carcinoma of Lungactive not recruiting589
2026-07 est.P1/P2MBrace TherapeuticsNCT06014658 Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid TumorsCancerrecruiting130
2026-07 est.P3ItalfarmacoNCT06093672 Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia VeraPolycythemia Verarecruiting220
2026-07 est.P2/P3Curadel Surgical Innovations, Inc.NCT06101745 Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic SurgeryInjury of Ureter During Surgery (Disorder)recruiting336
2026-07 est.P3Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06297655 A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia AHemophilia Aactive not recruiting60
2026-07 est.P1/P2Intelligem Therapeutics Australia Pty Ltd.NCT06310967 A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney DiseaseHyperuricemia; Hypouricemia, Renalrecruiting60
2026-07 est.P2Visirna Therapeutics HK LimitedNCT06322628 A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH PatientsNashactive not recruiting48
2026-07 est.P1/P2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06372626 Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.Neuroendocrine Carcinomaunknown93
2026-07 est.P2Mabwell (Shanghai) Bioscience Co., Ltd.NCT06492005 A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast CancerTriple-Negative Breast Cancerrecruiting160
2026-07 est.P2TLC Biopharmaceuticals, Inc.NCT06574269 A Study on TLC590 for Managing Postsurgical PainPostsurgical Pain Managementrecruiting120
2026-07 est.P2AbbVie ABBVNCT06682988 A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary PeritoneAdvanced High-Grade Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancersrecruiting110
2026-07 est.P3Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06738251 A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial CarcinomaAdvanced Urothelial Carcinomarecruiting402
2026-07 est.P3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06833307 The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque PsoriasisChildren and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasisnot yet recruiting90
2026-07 est.P2ReproNovo ApsNCT06993155 A Clinical Trial Evaluating the Efficacy and Safety of Leflutrozole on Testicular FunctionSemen Qualityrecruiting200
2026-07 est.P2Aphaia Pharma US LLCNCT07008456 A Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations Combined With a Gel CompObese With Comorbidities; Obese Patients (BMI ≥ 30 kg/m²)recruiting102
2026-07 est.P1/P2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT07044908 TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal CancerRAS/BRAF Wild Type Colorectal Cancerrecruiting72
2026-07 est.P1/P2Qilu Pharmaceutical Co., Ltd.NCT07102004 Study of MHB088C for Patients With Advanced Solid Malignant TumorsAdvanced/Metastatic Solid Tumorsrecruiting515
2026-07 est.P2Saptalis Pharmaceuticals LLCNCT07146217 Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial InfectionBacterial Infectionsnot yet recruiting30
2026-07 est.P2Marea TherapeuticsNCT07199309 A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant CholesterolHypertriglyceridemiarecruiting30
2026-07 est.P3Staidson (Beijing) Biopharmaceuticals Co., LtdNCT07208591 To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress SyndromeAcute Respiratory Distress Syndrome (ARDS)recruiting406
2026-07 est.P2Annexin Pharmaceuticals ABNCT07259928 Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein OcclusionNon-Proliferative Diabetic Retinopathy; Retinal Vein Occlusionrecruiting12
2026-07 est.P3Colgate Palmolive CLNCT07499115 Efficacy of a Toothpaste in Reducing Plaque, Gingivitis, and Gingival BleedingPlaque, Dental; Gingivitisnot yet recruiting90
2026-07-01P1/P2Erasca, Inc. ERASNCT04866134 A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid TumorsAdvanced or Metastatic Solid Tumorscompleted85
2026-07-01 est.P1/P2Scancell Ltd SCNLDNCT05329532 Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal CancerTriple Negative Breast Cancer; Renal Cell Cancer; High Grade Ovarian Serous Adenocarcinoma; Squamousrecruiting168
2026-07-01P3Amgen AMGNNCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AAtopic Dermatitisterminated2621
2026-07-01 est.P2Sinocelltech Ltd.NCT06197009 Efficacy and Safety of SCT650C in Participants With Axial SpondyloarthritisAxial Spondyloarthritisunknown168
2026-07-01 est.P2/P3Shanghai JMT-Bio Inc.NCT06319313 Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung CancerSquamous Cell Non-small Cell Lung Cancernot yet recruiting534
2026-07-01P2Eli Lilly and Company LLYNCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight WObesity; Overweightcompleted367
2026-07-02P2/P3argenx ARGXNCT05523167 A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.Active Idiopathic Inflammatory Myopathy; Myositis; Dermatomyositis; Polymyositis; Immune-Mediated Necompleted265
2026-07-02P2ResoTher PharmaNCT06465303 A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)ST Elevation Myocardial Infarctioncompleted66
2026-07-02P2Citryll BVNCT06567470 A Study With CIT-013 in RA PatientsRheumatoid Arthritiscompleted96
2026-07-02P3Medigen Vaccine Biologics Corp.NCT07178522 A Study to Evaluate the Immunogenicity and Safety of an EV71 Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 YearsEnterovirus 71 Inactivated Vaccineactive not recruiting379
2026-07-02P3Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07790120 A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypeUncontrolled Hypertension; Resistant Hypertensioncompleted256
2026-07-03 est.P3Boehringer IngelheimNCT06370871 Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue SarcomaAdvanced Soft Tissue Sarcoma; Undifferentiated Pleomorphic Sarcoma (UPS); Myxofibrosarcoma (MFS)withdrawn
2026-07-05P3Colgate Palmolive CLNCT07398378 Clinical Investigation of Oral Malodor for Max Fresh Toothpaste Containing Zinc Citrate Versus a Commercially Available Regular Fluoride ToothpasteOral Malodorcompleted80
2026-07-06P3AstraZeneca AZNNCT05261399 Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatCarcinoma; Non-Small-Cell Lungactive not recruiting341
2026-07-06P2Eli Lilly and Company LLYNCT05536804 A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesOverweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2Dcompleted134
2026-07-06P2Uniquity One (UNI)NCT06496607 A Study to Evaluate Solriktug in Adult Participants With AsthmaAsthmacompleted145
2026-07-07P3Grifols Therapeutics LLC GRFSNCT01983241 Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin DeficiePulmonary Emphysema in Alpha-1 PI Deficiencycompleted345
2026-07-07P3UCB Biopharma SRLNCT04666610 A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or JuChildhood Absence Epilepsy; Juvenile Absence Epilepsycompleted154
2026-07-07P2AstraZeneca AZNNCT06194448 To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR MutationsLung Canceractive not recruiting76
2026-07-07P3CSL BehringNCT06399289 Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX TherapyHemophilia Bcompleted23
2026-07-07P2Ardelyx ARDXNCT06553547 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 YrsIrritable Bowel Syndrome With Constipation (IBS-C)completed72
2026-07-08P1/P2Jasper Therapeutics, Inc. JSPRNCT06162728 Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous UrtChronic Spontaneous Urticariacompleted87
2026-07-08P2Sirtsei Pharmaceuticals, Inc.NCT06254612 A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive DisorderMajor Depressive Disordercompleted497
2026-07-08P3Amylyx Pharmaceuticals Inc. AMLXNCT06747468 Avexitide for Treatment of Post-Bariatric HypoglycemiaPost Bariatric Hypoglycemiaactive not recruiting75
2026-07-09P3Bristol-Myers Squibb BMYNCT04039607 A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaHepatocellular Carcinomacompleted732
2026-07-09P3Regeneron Pharmaceuticals REGNNCT06548100 A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized LipodystrophGeneralized Lipodystrophycompleted9
2026-07-09 est.P2Hansoh BioMedical R&D CompanyNCT06926582 A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque PsoriasisPsoriasisnot yet recruiting305
2026-07-09P2Shanghai Minwei Biotechnology Co., LtdNCT07791524 Phase 2 Study of MWN109 Tablet in Participants With Overweight or ObesityOverweight , Obesitycompleted255
2026-07-10P3BioNTech SE BNTXNCT05543616 A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy ChildrenSARS-CoV-2 Virus; Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19completed4338
2026-07-10P3AstraZeneca AZNNCT06564844 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete TuNon-small Cell Lung Canceractive not recruiting25
2026-07-10P3Ultragenyx Pharmaceutical Inc RARENCT06617429 Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)Angelman Syndrometerminated129
2026-07-10 est.P2Shanghai Henlius BiotechNCT07269782 A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLCNon Small Cell Lung Cancerrecruiting60
2026-07-10 est.P1/P2Shanxi Kangbao Biological Product Co., Ltd.NCT07433387 Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected IndividualsHIVrecruiting30
2026-07-13P1/P2GlaxoSmithKlineNCT06405230 Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker PositroLung Cancer, Non-Small Cellterminated2
2026-07-13P3EyePoint Pharmaceuticals, Inc. EYPTNCT06668064 A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56Wet Age Related Macular Degeneration; wAMDactive not recruiting400
2026-07-13P2Aperta Biosciences, LLCNCT06720896 A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in PatiBlepharitiscompleted66
2026-07-13P2HK inno.N CorporationNCT07073677 A Study to Evaluate the Efficacy and Safety of IN-115314 Ointment in Mild to Moderate Atopic Dermatitis Adult PatientsMild to Moderate Atopic Dermatitisrecruiting162
2026-07-14P3Chiesi Farmaceutici S.p.A.NCT05164341 Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PLPartial Lipodystrophycompleted69
2026-07-14P3AstraZeneca AZNNCT05583227 Efficacy and Safety of Tezepelumab in Patients With Eosinophilic EsophagitisEosinophilic Esophagitisactive not recruiting368
2026-07-14P1/P2Ossium Health, Inc.NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic MalignAcute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Acute Biphenotypic Leukemia; Aactive not recruiting12
2026-07-14P3AbbVie ABBVNCT05995340 ELAPR002f Injectable Gel in the Treatment of Atrophic Acne ScarsAtrophic Acne Scarscompleted157
2026-07-14P2Takeda TAKNCT06254950 A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative ColitisUlcerative Colitisactive not recruiting213
2026-07-14P2/P3EyeBiotech Ltd.NCT06571045 A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEDiabetic Macular Edema (DME)active not recruiting984
2026-07-14P2GlaxoSmithKlineNCT06748053 A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled AsthmaAsthmaactive not recruiting307
2026-07-14P3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06827431 The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With DepressionMajor Depressive Disorder (MDD)completed786
2026-07-14P3BayerNCT07023341 A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic CardiomyopathyObstructive Hypertrophic Cardiomyopathyactive not recruiting36
2026-07-14P2Atom Therapeutics Co., LtdNCT07145229 Safety and Efficacy of ABP-745 in Participants With an Acute Gout FlareAcute Gouty Arthritis; Gout Flare; Gout Flares; Acute Gout Flarecompleted479
2026-07-14P2Jiangsu HengRui Medicine Co., Ltd.NCT07446309 Safety and Efficacy of HRS-9190 Compared to Cisatracurium for Continuous Intravenous Infusion in AdultsNeuromuscular Blockadecompleted67
2026-07-15P3Jazz Pharmaceuticals JAZZNCT05152147 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinomaactive not recruiting920
2026-07-15 est.P3Alexion Pharmaceuticals, Inc.NCT05644561 Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia GravisGeneralized Myasthenia Gravis; gMGactive not recruiting12
2026-07-15P3AbbVie ABBVNCT05814627 Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to SeRheumatoid Arthritiscompleted487
2026-07-15P1/P2EMD Serono Research & Development Institute, Inc.NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)Non-Small Cell Lung Cancercompleted61
2026-07-15P3Jiangsu HengRui Medicine Co., Ltd.NCT06057610 A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast CancerHER2-PositiveRecurrent or Metastatic Breast Canceractive not recruiting868
2026-07-15 est.P2Can-Fite BioPharma CANFNCT06387342 Namodenoson Treatment of Advanced Pancreatic CancerPancreatic Adenocarcinoma; Pancreatic Cancerrecruiting20
2026-07-15 est.P2JemincareNCT06509334 Trial of JYB1904 in Chronic Spontaneous Urticaria.Chronic Spontaneous Urticariarecruiting135
2026-07-15 est.P2Immunis, Inc.NCT06600581 Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle WeaknessMuscle Performance; Sarcopenic Obesityactive not recruiting55
2026-07-15P3Definium Therapeutics US, Inc. DFTXNCT06741228 A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)Generalized Anxiety Disorderactive not recruiting214
2026-07-15 est.P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07116824 HB1801 Combined Treatment of HER2-positive Breast CancerHER2-positive Breast Cancernot yet recruiting80
2026-07-15P2Citryll BVNCT07147959 PET-Based Imaging of Radiolabeled CIT-013RAcompleted7
2026-07-15P3Sinovac Biotech Co., Ltd SVANCT07416110 Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies VaccineRabies (Healthy Volunteers)active not recruiting912
2026-07-15P2Clear Scientific, Inc.NCT07459166 A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone BlockadeFentanyl Overdose; Fentanyl Poisoningcompleted16
2026-07-15 est.P3Sinovac (Dalian) Vaccine Technology Co., Ltd.NCT07475000 Second Dose of Varicella Vaccine in Healthy ChildrenVaricella (Chickenpox); Varicella Immunisationrecruiting300
2026-07-15P2Arctic TherapeuticsNCT07774364 Safety and Efficacy of Topical AT-004 1% in Participants With Acne Vulgaris (AV)Acne Vulgaris on the Facecompleted63
2026-07-16P3Novartis Pharmaceuticals NVSNCT04023552 Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVDCardiovascular Disease and Lipoprotein(a)completed8323
2026-07-16P2Immunovant Sciences GmbH IMVTNCT07188844 An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Chronic Inflammatory Demyelinating Polyneuropathyterminated26
2026-07-17P2Connect Biopharm LLC CNTBNCT06940141 Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)Asthma Acutecompleted160
2026-07-18P3Fujian Shengdi Pharmaceutical Co., Ltd.NCT06649344 A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2Type 2 Diabetescompleted884
2026-07-18 est.P2Keymed Biosciences Co.LtdNCT06947980 Study of CM512 in Patients With Moderate-to-Severe Atopic DermatitisAtopic Dermatitisrecruiting200
2026-07-19 est.P3AbbVie ABBVNCT05316220 A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative ColitisUlcerative Colitis (UC)withdrawn
2026-07-20P2Immunovant Sciences GmbH IMVTNCT05581199 To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDPChronic Inflammatory Demyelinating Polyneuropathyterminated94
2026-07-20P2Vertex Pharmaceuticals Incorporated VERXNCT06794996 Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without ComorbiditiesProteinuric Kidney Diseasecompleted42
2026-07-20P3GlaxoSmithKlineNCT07220109 A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of RespRespiratory Syncytial Virus Infectionsactive not recruiting750
2026-07-21P2Takeda TAKNCT02616302 A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years OldGastroesophageal Reflux Disease (GERD)completed71
2026-07-21P3Bristol-Myers Squibb BMYNCT04036435 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With PsoriasisPsoriasiscompleted1466
2026-07-21P3Novartis Pharmaceuticals NVSNCT05147220 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)Relapsing Multiple Sclerosisactive not recruiting1000
2026-07-21P3PTC Therapeutics PTCNCT05166161 A Long-Term Safety Study of PTC923 in Participants With PhenylketonuriaPhenylketonuriacompleted247
2026-07-21P3Eli Lilly and Company LLYNCT06649045 A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightOSA; Overweight or Obesitycompleted712
2026-07-21P3Pharvaris Netherlands B.V. PHVSNCT06669754 Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAEHereditary Angioedema (HAE)completed85
2026-07-21P2Jasper Therapeutics, Inc. JSPRNCT06736262 A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic UrticariaUrticaria Chronicterminated67
2026-07-21P2SPARK Biopharma SPKLFNCT06747923 SB17170 Phase 2 Trial in IPF PatientsIPF; Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF)completed32
2026-07-21P1/P2Regeneron Pharmaceuticals REGNNCT07218770 A Study of REGN7041 for Active Noninfectious Uveitis in Adult ParticipantsActive Noninfectious Uveitis Affecting the Posterior Segmentterminated1
2026-07-22P3Hoffmann-La RocheNCT04543617 A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed FolloEsophageal Squamous Cell Carcinomacompleted760
2026-07-22P3UCB Biopharma SRLNCT04901195 A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaHidradenitis Suppurativacompleted658
2026-07-22P3Novartis Pharmaceuticals NVSNCT05156281 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)Relapsing Multiple Sclerosisactive not recruiting1007
2026-07-22P3RDC Clinical Pty LtdNCT05232279 Effect of Testofen on Erectile Function in an Adult Male PopulationErectile Dysfunctioncompleted64
2026-07-22P2Aptabio Therapeutics, Inc.NCT05758896 Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCIContrast Induced Acute Kidney Injurycompleted218
2026-07-22P2Gilead Sciences GILDNCT06101329 Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)Pre-Exposure Prophylaxis of HIV Infectionactive not recruiting253
2026-07-22P1/P2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06233292 A Study of ZG005 in Patients With Advanced Solid TumorsSolid Tumorscompleted125
2026-07-22P3Takeda TAKNCT06439342 A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) InfectionsCytomegalovirus (CMV)completed20
2026-07-22P2Beijing Inno Medicine Co., Ltd.NCT06700720 YN001-004 in Patients With Coronary Atherosclerosis in AustraliaCoronary Artery Disease; Coronary Atherosclerotic Diseaseterminated3
2026-07-22P2Hoffmann-La RocheNCT06863961 A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic DermatitisAtopic Dermatitisactive not recruiting162
2026-07-22P2/P3Qlaris Bio, Inc.NCT07354516 Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular HypertensionOAG - Open-Angle Glaucoma; OHT - Ocular Hypertensioncompleted64
2026-07-23P2Pfizer PFENCT03307980 Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia BHemophilia Bterminated21
2026-07-23P1/P2Merck Sharp & Dohme LLC MRKNCT04626518 Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)Carcinoma, Renal Cellcompleted263
2026-07-23P1/P2Binhui Biopharmaceutical Co., Ltd.NCT05235074 OH2 Oncolytic Viral Therapy in Central Nervous System TumorsCentral Nervous System Tumorscompleted40
2026-07-23P3Amgen AMGNNCT06104124 A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease ActivitySjogren's Syndromecompleted651
2026-07-23P3Avidity Biosciences, Inc.NCT06411288 Global Study of Del-desiran for the Treatment of DM1DM1; Myotonic Dystrophy; Myotonic Dystrophy 1; Myotonia; Myotonic Dystrophy Type 1 (DM1); Dystrophy completed159
2026-07-23 est.P2/P3Shanghai Vitalgen BioPharma Co., Ltd.NCT06432140 A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC DeficiencyAromatic L-amino Acid Decarboxylase Deficiencyactive not recruiting13
2026-07-23P2Evommune, Inc. EVMNNCT07150845 Phase 2b Study of EVO756 in Adults With Atopic DermatitisAtopic Dermatitiscompleted121
2026-07-23P2Verdiva Bio Dev LimitedNCT07281937 A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesObesity; Overweightcompleted206
2026-07-24P3ModernaTX, Inc.NCT06067230 A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk AdultsRespiratory Syncytial Viruscompleted1153
2026-07-24P3BioNTech SE BNTXNCT07222384 A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe CCOVID-19; SARS-COV-2 Infectioncompleted344
2026-07-27 est.P3AstraZeneca AZNNCT04884360 D9319C00001- 1L OC Mono Global RCTOvarian Canceractive not recruiting366
2026-07-27P1/P2Immunis, Inc.NCT05211986 Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.Muscle Atrophycompleted13
2026-07-27P2Gilead Sciences GILDNCT06101342 Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)Pre-Exposure Prophylaxis of HIV Infectionactive not recruiting181
2026-07-27P2AbbVie ABBVNCT06236880 A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDDMajor Depressive Disordercompleted126
2026-07-27P2Beijing Continent Pharmaceutical Co, Ltd.NCT07417553 A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver FibrosisChronic Hepatitis B-related Liver Fibrosiscompleted67
2026-07-28P3ReGenTree, LLCNCT05555589 Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2Neurotrophic Keratopathycompleted70
2026-07-28 est.P1/P2Lantern Pharma Inc. LTRNNCT05933265 Study of LP-184 in Patients With Advanced Solid TumorsAdvanced Solid Tumor; Metastatic Solid Tumor; GBM; TNBC - Triple-Negative Breast Cancer; NSCLC; Pancactive not recruiting64
2026-07-28P3Beijing Continent Pharmaceutical Co, Ltd.NCT07343778 A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver CirrhosisChronic Hepatitis B With Hepatic Fibrosiscompleted337
2026-07-29P3Mirum Pharmaceuticals, Inc. MIRMNCT06553768 Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)active not recruiting90
2026-07-29P2Processa Pharmaceuticals PCSANCT06568692 A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerBreast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancerterminated20
2026-07-29P1/P2Incyte Corporation INCYNCT06873789 A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid TumorsSolid Tumors; Advanced Solid Tumors; Metastatic Solid Tumorsterminated9
2026-07-29 est.P2Lanzhou Institute of Biological Products Co., LtdNCT07445815 A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal AntibodyRabies (Healthy Volunteers)not yet recruiting200
2026-07-30P3Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)NCT04724369 Open-Label Study of 18F-mFBG for Imaging NeuroblastomaNeuroblastomacompleted43
2026-07-30P3Biogen BIIBNCT04729907 A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who TMuscular Atrophy, Spinalcompleted115
2026-07-30 est.P3Pfizer PFENCT05261139 EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not HoCOVID-19recruiting160
2026-07-30 est.P3Jiangsu HengRui Medicine Co., Ltd.NCT05320692 A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular CarcinomaHepatocellular Carcinomaactive not recruiting423
2026-07-30 est.P1/P2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT05744427 Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid TumorsAdvanced Solid Tumoractive not recruiting725
2026-07-30 est.P2Shanghai Institute Of Biological ProductsNCT06194656 Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinomarecruiting81
2026-07-30 est.P2Levee Medical, Inc.NCT06275945 Feasibility Study of A VoRo UrologIc ScaffolD (ARID)Stress Urinary Incontinence; Radical Prostatectomyactive not recruiting40
2026-07-30P2atai Therapeutics, Inc.NCT06524830 A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)Treatment Resistant Depressioncompleted142
2026-07-30P2Sanofi SNYNCT06637631 A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.Crohn's Diseaseterminated105
2026-07-30P3Gan & Lee Pharmaceuticals.NCT06777238 A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by DiType 2 Diabetes Mellitus (T2DM)completed274
2026-07-30 est.P3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT06927986 Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01)EGFR-mutated Locally Advanced or Metastatic NSCLCrecruiting380
2026-07-30P2Connect Biopharm LLC CNTBNCT06940154 Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)COPD Acute Exacerbationcompleted159
2026-07-30P2Altimmune, Inc. ALTNCT06987513 RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightAlcohol Use Disorder (AUD)completed100
2026-07-30 est.P1/P2NSC-TherapeuticsNCT06995573 A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's DiseaseAlzheimer Diseaserecruiting90
2026-07-30 est.P2InventisBio Co., LtdNCT07035041 A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative ColitisUC - Ulcerative Colitis; Moderately to Severely Active Ulcerative Colitisactive not recruiting120
2026-07-30P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07314060 A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular PsoriasisGeneralized Pustular Psoriasisterminated36
2026-07-30 est.P2Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07579936 A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing RegimensPostmenopausal Women With Osteoporosisrecruiting200
2026-07-31 est.P2OHB Neonatology Ltd.NCT03253263 A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature InfantsBronchopulmonary Dysplasia; Chronic Lung Disease of Prematurity; Intraventricular Hemorrhage; Retinoactive not recruiting295
2026-07-31 est.P2Xynomic Pharmaceuticals, Inc.NCT03936153 Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)Diffuse Large B-cell Lymphoma (DLBCL)recruiting170
2026-07-31 est.P2Frantz Viral Therapeutics, LLCNCT04098744 Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)CIN 2/3; HPV Infection; Pre-Cancerous Dysplasia; Cervical Dysplasia; HPV Related Diseaserecruiting78
2026-07-31P3UCB Biopharma SRLNCT04225871 Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia GravisGeneralized Myasthenia Graviscompleted200
2026-07-31 est.P3Jiangsu HengRui Medicine Co., Ltd.NCT04639180 A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence AfteHepatocellular Carcinoma (HCC)active not recruiting687
2026-07-31 est.P1/P2Idience Co., Ltd.NCT04725994 Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric CancerGastric Canceractive not recruiting87
2026-07-31P2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT05445908 SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast CancerTriple-negative Breast Cancer and HR+/HER2- BCcompleted184
2026-07-31 est.P3Kringle Pharma, Inc.NCT05627648 Phase 3 Study of KP-100LI in Subjects With Vocal Fold ScarVocal Fold Scaractive not recruiting62
2026-07-31P2SyntaraNCT05904717 Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour DisorderREM Sleep Behavior Disordercompleted40
2026-07-31 est.P2Hansoh BioMedical R&D CompanyNCT06112704 HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid TumorsAdvanced Solid Tumorrecruiting220
2026-07-31P1/P2Pfizer PFENCT06137742 A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial HypertensionPulmonary Arterial Hypertensioncompleted97
2026-07-31P2Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06297226 Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple MyelomaMultiple Myelomarecruiting230
2026-07-31 est.P1/P2YourChoice Therapeutics, Inc.NCT06542237 Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy MalesMale Contraceptionrecruiting88
2026-07-31P3Hoffmann-La RocheNCT06624059 A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung Cancercompleted11
2026-07-31 est.P1/P2NEC Bio B.VNCT06631079 Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid TumorsSolid Tumoractive not recruiting20
2026-07-31P1/P2SK Bioscience Co., Ltd.NCT06680128 A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy AdulJapanese Encephalitis Virus Diseasecompleted161
2026-07-31 est.P3SK Plasma Co., Ltd.NCT06738901 An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a PHemophilia A, Severenot yet recruiting55
2026-07-31 est.P2GlaceumNCT06845553 A Study to Assess the Efficacy and Safety of Vutiglabridin in Knee Osteoarthritis PatientsKnee Osteoarthritis (Knee OA)recruiting60
2026-07-31P2Ono Pharmaceutical Co., Ltd.NCT06881836 A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's DiseaseAlzheimer Diseasecompleted260
2026-07-31 est.P1/P2Genrix (Shanghai) Biopharmaceutical Co., Ltd.NCT07090954 A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple MyelomaMultiple Myelomanot yet recruiting32
2026-07-31 est.P1/P2Shanghai JMT-Bio Inc.NCT07140809 a Phase 1b/2a Study of JMT202 Injection in Participants With HypertriglyceridemiaHypertriglyceridemiarecruiting48
2026-07-31 est.P2Clarent Biopharma, Inc.NCT07204639 Safety and Efficacy of CBP-0276 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in SubjectsPsoriasisrecruiting100
2026-07-31 est.P3MAXVAX Biotechnology Limited Liability CompanyNCT07272434 Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)Respiratory Syncytial Virus (RSV)recruiting25000
2026-07-31 est.P2Neurodawn Pharmaceutical Co., Ltd.NCT07275762 Y-4 to Treat the Postherpetic NeuralgiaPostherpetic Neuralgia; Y-4; Pregabalinrecruiting160
2026-07-31 est.P2Oui Therapeutics, Inc.NCT07316088 Determining the Potential for Efficacy of OTX-601 in Reducing PTSD SymptomsPTSD; Post Traumatic Stress Disorderactive not recruiting40
2026-07-31 est.P2Linno Pharmaceuticals, Inc.NCT07387302 SLN12140 in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in ChinaParoxysmal Nocturnal Hemoglobinuria (PNH)not yet recruiting10
2026-07-31 est.P1/P2Juvena TherapeuticsNCT07397468 To studyJUV-161 Administered to Healthy Volunteers Undergoing Unilateral Lower Limb Immobilization (ULLI)Healthy Volunteersrecruiting36

← 2026-06 | 2026-08 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.